Immunovant Stock Forecast, Price & News

Immunovant (NASDAQ:IMVT) Frequently Asked Questions

Is Immunovant a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last year. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Immunovant stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IMVT, but not buy additional shares or sell existing shares.
View analyst ratings for Immunovant or view top-rated stocks.

How has Immunovant's stock price been impacted by Coronavirus?

Immunovant's stock was trading at $14.14 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMVT shares have decreased by 50.2% and is now trading at $7.04.
View which stocks have been most impacted by COVID-19.

Are investors shorting Immunovant?

Immunovant saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 2,310,000 shares, a decrease of 28.3% from the December 15th total of 3,220,000 shares. Based on an average daily volume of 635,700 shares, the short-interest ratio is currently 3.6 days. Approximately 5.7% of the shares of the stock are sold short.
View Immunovant's Short Interest.

When is Immunovant's next earnings date?

Immunovant is scheduled to release its next quarterly earnings announcement on Tuesday, February 15th 2022.
View our earnings forecast for Immunovant.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) announced its quarterly earnings results on Friday, November, 5th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.26) by $0.09.
View Immunovant's earnings history.

What price target have analysts set for IMVT?

10 brokerages have issued 1-year price targets for Immunovant's shares. Their forecasts range from $7.00 to $35.00. On average, they expect Immunovant's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 113.1% from the stock's current price.
View analysts' price targets for Immunovant or view top-rated stocks among Wall Street analysts.

Who are Immunovant's key executives?

Immunovant's management team includes the following people:

• Dr. Peter Salzmann M.B.A., M.D., CEO & Director (Age 53, Pay $1.02M)
• Ms. Pamela Yanchik Connealy M.B.A., Chief Financial Officer (Age 59, Pay $558.94k)
• Dr. Julia G. Butchko Ph.D., Chief Devel. & Technology Officer (Age 50, Pay $531k)
• Ms. Lauren Schrier M.B.A., VP of Marketing
• Ms. Beverly Paperiello, Sr. VP of Program Strategy, Chief Medical Officer & Chief of Staff
• Dr. Alan Jacobs M.D., VP & Head of Neurology Devel.
• Dr. William L. Macias M.D., Ph.D., Chief Medical Officer (Age 63)

Who are some of Immunovant's key competitors?

Some companies that are related to Immunovant include Kodiak Sciences (KOD), Twist Bioscience (TWST), SpringWorks Therapeutics (SWTX), BioCryst Pharmaceuticals (BCRX), Relay Therapeutics (RLAY), Iovance Biotherapeutics (IOVA), Bavarian Nordic A/S (BVNRY), Adaptive Biotechnologies (ADPT), ImmunityBio (IBRX), Kymera Therapeutics (KYMR), Exscientia (EXAI), Recursion Pharmaceuticals (RXRX), Valneva (VALN), Revolution Medicines (RVMD) and Sana Biotechnology (SANA).
View all of IMVT's competitors.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include salesforce.com (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

What is Immunovant's stock symbol?

Immunovant trades on the NASDAQ under the ticker symbol "IMVT."

Who are Immunovant's major shareholders?

Immunovant's stock is owned by many different retail and institutional investors. Top institutional shareholders include Strs Ohio (0.02%). Company insiders that own Immunovant stock include Atul Pande, Douglas J Hughes, George V Migausky, Julia G Butchko, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends for Immunovant.

Which institutional investors are buying Immunovant stock?

IMVT stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Immunovant stock in the last two years include Atul Pande, Douglas J Hughes, George V Migausky, Julia G Butchko, and Sciences Ltd Roivant.
View insider buying and selling activity for Immunovant or or view top insider-buying stocks.

How do I buy shares of Immunovant?

Shares of IMVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Immunovant's stock price today?

One share of IMVT stock can currently be purchased for approximately $7.04.

How much money does Immunovant make?

Immunovant has a market capitalization of $809.60 million. The company earns $-107.43 million in net income (profit) each year or ($1.27) on an earnings per share basis.

How many employees does Immunovant have?

Immunovant employs 68 workers across the globe.

What is Immunovant's official website?

The official website for Immunovant is www.immunovant.com.

Where are Immunovant's headquarters?

Immunovant is headquartered at 320 WEST 37TH STREET, NEW YORK NY, 10018.

How can I contact Immunovant?

Immunovant's mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company can be reached via phone at 917-580-3099 or via email at [email protected].